• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
University Hospital, Geneva - Product Pipeline Review - Q4 2010 Product Image

University Hospital, Geneva - Product Pipeline Review - Q4 2010

  • ID: 1446640
  • December 2010
  • 38 pages
  • GlobalData

University Hospital, Geneva – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “University Hospital, Geneva – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by University Hospital, Geneva.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University Hospital, Geneva with READ MORE >



List of Tables
List of Figures
University Hospital, Geneva Snapshot
University Hospital, Geneva Overview
Key Information
Key Facts
University Hospital, Geneva – Research and Development Overview
Key Therapeutic Areas
University Hospital, Geneva – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University Hospital, Geneva – Pipeline Products Glance
University Hospital, Geneva – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University Hospital, Geneva Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
University Hospital, Geneva – Drug Profiles
Midazolam
Product Description
Mechanism of Action
R&D Progress
Nadropin
Product Description
Mechanism of Action
R&D Progress
progesterone
Product Description
Mechanism of Action
R&D Progress
Actos + Pegasys + Copegus
Product Description
Mechanism of Action
R&D Progress
Adalimumab
Product Description
Mechanism of Action
R&D Progress
Epoetinum
Product Description
Mechanism of Action
R&D Progress
Erythromycin
Product Description
Mechanism of Action
R&D Progress
flurbiprofen + fluconazole
Product Description
Mechanism of Action
R&D Progress
Ketamine
Product Description
Mechanism of Action
R&D Progress
Nicotine
Product Description
Mechanism of Action
R&D Progress
Nicotinell
Product Description
Mechanism of Action
R&D Progress
Salmon calcitonin
Product Description
Mechanism of Action
R&D Progress
ferucarbotran
Product Description
Mechanism of Action
R&D Progress
University Hospital, Geneva – Pipeline Analysis
University Hospital, Geneva – Pipeline Products by Therapeutic Class
University Hospital, Geneva Pipeline Products By Target
University Hospital, Geneva – Pipeline Products by Route of Administration
University Hospital, Geneva – Pipeline Products by Molecule Type
University Hospital, Geneva - Dormant Projects
University Hospital, Geneva – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS